Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 2,000 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 2,000 shares of the stock in a transaction dated Thursday, January 2nd. The shares were bought at an average cost of $11.97 per share, with a total value of $23,940.00. Following the completion of the transaction, the chief executive officer now owns 5,543,702 shares of the company’s stock, valued at approximately $66,358,112.94. This represents a 0.04 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Snehal Patel also recently made the following trade(s):

• On Tuesday, January 7th, Snehal Patel purchased 1,800 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $13.75 per share, with a total value of $24,750.00.
• On Monday, December 30th, Snehal Patel acquired 3,200 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $11.12 per share, for a total transaction of $35,584.00.

Greenwich LifeSciences Trading Down 3.3 %

Greenwich LifeSciences stock opened at $13.35 on Thursday. The company has a fifty day simple moving average of $13.15 and a 200-day simple moving average of $14.13. The stock has a market cap of $175.49 million, a P/E ratio of -16.69 and a beta of 1.66. Greenwich LifeSciences, Inc. has a 12-month low of $8.00 and a 12-month high of $21.44.

Institutional Trading of Greenwich LifeSciences

A number of institutional investors have recently bought and sold shares of the business. State Street Corp increased its holdings in shares of Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after acquiring an additional 3,005 shares during the last quarter. Rhumbline Advisers acquired a new position in Greenwich LifeSciences in the second quarter valued at approximately $117,000. Barclays PLC increased its stake in Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after purchasing an additional 6,538 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Greenwich LifeSciences in the second quarter valued at approximately $264,000. Finally, Garden State Investment Advisory Services LLC acquired a new stake in Greenwich LifeSciences during the third quarter worth approximately $253,000. 4.16% of the stock is owned by hedge funds and other institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.